ClinicalTrials.gg
RecruitingNCT05893407PerCEUSUpdated Jun 19, 2025

Brain PERfusion Evaluation by Contrast-Enhanced UltraSound

An observational study in Cerebral Hemorrhage, Subarachnoid Hemorrhage and Ischemic Stroke, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Cerebral Hemorrhage with a site in France — 11 open to participants now, 11 under way, 2 of them phase 3. Cerebral Hemorrhage · France.

Planned enrollment
8th of 11
60 · median 455
Started
2023
the only one that year
Observational
11 of 24
7 open now
Primary completion
2025-07
later than 0 of 10 live
Registered
15th of 24
by date
Lead sponsor
3 of 24
Assistance Publique - Hôpitaux de Paris

Among the 24 studies in Cerebral Hemorrhage with a site in France, this one is the 8th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2023, is one of 11 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 15th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

11 of the 24 studies in Cerebral Hemorrhage with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Cerebral Hemorrhage with a site in France, or all of them as a file.
02

Study summary

The objective of the study is to assess brain tissue perfusion by contrast-enhanced ultrasound perfusion imaging (PerCEUS) in acute brain injuries. More precisely, it aims :

  • to evaluate the heterogeneity of brain perfusion and thus diagnose brain tissue hypoperfusion with contrast-enhanced ultrasound.
  • to correlate contrast-enhanced ultrasound with perfusion measurements by usual multimodal monitoring.
Read the detailed description

The main aim is to evaluate the heterogeneity of brain perfusion, thus diagnosing brain tissue hypoperfusion with PerCEUS, then to correlate it with the usual multimodal monitoring.

Earlier after hospitalization in neurointensive care, when the study physician needs to realize a contrast ultrasound imaging and without delaying any emergency procedure, a PerCEUS will be performed in patients with an acute brain injury. After acquisition, data from PerCEUS will be transferred to an external evaluation unit and analysed offline, using commercially available software Qlab (Philips ®). According to the localization of acute brain injuries with magnetic resonance imaging (MRI) and/or computed tomography (CT), several regions-of-interest (ROI, at least three in each area) will be chosen :

  • Area 1 : in the core of the lesion (supposed non perfused)
  • Area 2 : just next to the lesion (supposed hypoperfused)
  • Area 3 : in the saner hemisphere, symmetrically to area 2 each time it's possible (supposed well-perfused).

Every parameters of multimodal monitoring used at the moment of PerCEUS will be relieved :

  • intracranial pressure (ICP), cerebral perfusion pressure (CPP), mean arterial pressure (MAP)
  • mean flow velocity (MFV) by transcranial doppler (TCD)
  • regional cerebral oxygen saturation (rSO2) by Near infrared spectroscopy (NIRS)
  • jugular venous oximetry (SjvO2).

The actual PerCEUS measurement takes place at the bedside, is performed by the study physician, and takes about 5 minutes.

The trial duration per patient is 30 minutes, ending after 25 minutes of oversight

03

Conditions studied

  • Cerebral Hemorrhage
  • Subarachnoid Hemorrhage
  • Ischemic Stroke
  • Cerebrovascular Circulation
  • Perfusion

Keywords

  • Brain perfusion
  • Cerebral blood flow
  • Diagnostic imaging
  • Ultrasonography Doppler
  • Doppler ultrasound
  • Transcranial Doppler
  • Contrast enhanced ultrasound
  • Contrast-enhanced ultrasonography
  • Contrast ultrasound
  • Ultrasound perfusion imaging
  • Ultrasound contrast agent
  • Intra-cranial pressure
  • Intracerebral hematoma
  • Neurocritical care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients hospitalized in neurosurgical intensive care in Lariboisière Hospital, Paris, with acute brain injuries

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18
  • Intensive care unit admission for acute brain injury
  • Proven acute brain injury by CT and/or MRI
  • Requiring a contrast ultrasound imaging
  • of patient or relative

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Not sufficient temporal window
  • to Sonovue ® : acute coronary syndromes, severe ischemic heart disease (requiring revascularization), pulmonary arterial hypertension > 90 mmHg, right-left shunt, ARDS, dobutamine's use, known allergy or adverse reaction to Sonovue®
  • Patient on State Medical Assistance
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with acute brain injuries when a contrast ultrasound imaging is requested by the physician

    Contrast-enhanced ultrasound perfusion imaging (PerCEUS)

    Diagnostic Test: Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging

Interventions

  • Diagnostic testMeasuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging

    Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.

06

What researchers measure

Primary outcomes

  1. Evaluation of the heterogeneity of brain perfusion by time-to-peak (TPI) measurement

    Comparison between time-to-peak (TPI) intensities measured in ROIs in each area by PerCEUS

    Time frame: 30 minutes after PerCEUS

  2. Evaluation of the heterogeneity of brain perfusion by peak-intensities (PI) measurement

    Comparison between peak-intensities (PI) measured in ROIs in each area by PerCEUS

    Time frame: 30 minutes after PerCEUS

Secondary outcomes

  1. Correlation between PerCEUS parameters and cerebral perfusion as assessed by ICP and MAP

    Correlations test between TPI/PI and ICP/CPP/MAP

    Time frame: 30 minutes after PerCEUS

  2. Correlation between PerCEUS parameters and cerebral perfusion as assessed by TCD

    Correlations test between TPI/PI and MFV

    Time frame: 30 minutes after PerCEUS

  3. Correlation between PerCEUS parameters and cerebral perfusion as assessed by NIRS

    orrelations test between TPI/PI and rSO2

    Time frame: 30 minutes after PerCEUS

  4. Correlation between PerCEUS parameters and cerebral perfusion as assessed by SjvO2

    Correlations test between TPI/PI and SjvO2

    Time frame: 30 minutes after PerCEUS

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Eyding J, Krogias C, Wilkening W, Postert T. Detection of cerebral perfusion abnormalities in acute stroke using phase inversion harmonic imaging (PIHI): preliminary results. J Neurol Neurosurg Psychiatry. 2004 Jun;75(6):926-9. doi: 10.1136/jnnp.2003.026195. PubMed 15146019 ↗
  • Eyding J, Fung C, Niesen WD, Krogias C. Twenty Years of Cerebral Ultrasound Perfusion Imaging-Is the Best yet to Come? J Clin Med. 2020 Mar 17;9(3):816. doi: 10.3390/jcm9030816. PubMed 32192077 ↗
  • Vinke EJ, Kortenbout AJ, Eyding J, Slump CH, van der Hoeven JG, de Korte CL, Hoedemaekers CWE. Potential of Contrast-Enhanced Ultrasound as a Bedside Monitoring Technique in Cerebral Perfusion: a Systematic Review. Ultrasound Med Biol. 2017 Dec;43(12):2751-2757. doi: 10.1016/j.ultrasmedbio.2017.08.935. Epub 2017 Sep 28. PubMed 28964614 ↗
  • Fung C, Heiland DH, Reitmeir R, Niesen WD, Raabe A, Eyding J, Schnell O, Rolz R, Z Graggen WJ, Beck J. Ultrasound Perfusion Imaging for the Detection of Cerebral Hypoperfusion After Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2022 Aug;37(1):149-159. doi: 10.1007/s12028-022-01460-z. Epub 2022 Feb 24. PubMed 35211837 ↗
  • Bilotta F, Robba C, Santoro A, Delfini R, Rosa G, Agati L. Contrast-Enhanced Ultrasound Imaging in Detection of Changes in Cerebral Perfusion. Ultrasound Med Biol. 2016 Nov;42(11):2708-2716. doi: 10.1016/j.ultrasmedbio.2016.06.007. Epub 2016 Jul 27. PubMed 27475927 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2025, 24 months after the start.

Of 88 non-industry observational studies under Cerebral Hemorrhage, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 179. This study's planned 24 months is below that.

Counting every sponsor, half of 90 studies reached it within 62 months; a quarter within 27 and three quarters within 179.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2023
First posted
Jun 7, 2023
StartActual
Jul 21, 2023
Primary completionEst.
Jul 2025
CompletionEst.
Jul 2025
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05893407
Responsible party
Sponsor
First posted
Jun 7, 2023
Start date
Jul 21, 2023
Primary completion
Jul 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Jun 19, 2025

Study contacts

Romain BARTHELEMY, MD
Contact
romain.barthelemy@aphp.fr
+33 (0)1 49 95 85 15
Benjamin Glenn CHOUSTERMAN, MD PhD
Contact
benjamin.chousterman@aphp.fr
+33 (0)1 49 95 85 18
Romain BARTHELEMY, MD
principal investigator · AP-HP Lariboisière Hospital, Department of Anaesthesia and Intensive Care

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion